Schizophrenia
Conditions
Interventions
Administration of atypical antipsychotics (aripiprazole, olanzapine, risperidone , quetiapine)
Sponsors
Keio University School of Medicine Department of Neuropsychiatry
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with schizophrenia diagnosed by DSM-IV 2. Patients agree to participate in the study on a written informed consent form. 3. Patients should be able to receive examination and assessment on designated date. 4. Patients with a total score of GAF ranging 11 to 90 and a score of severity in CGI-SCH ranging 3 to 6 are included. Moreover, we select patients with chlorpromazine-conversion dosage of 150mg to 2000mg/ day at baseline.
Exclusion criteria
Exclusion criteria: 1. We exclude a patient who is comatose. 2. Patients who are heavily influenced by central nervous system depressant such as barbiturate and anesthetics. 3. Patients who are on adrenergic medication 4. Patients with a history of sensitivity to atypical antipsychotics 5. Patients who are diabetic or patients with a history of diabetes 6. Patients who are pregnant or breast feeding, have possibility of pregnancy 7. Patients who cannot be administered orally 8. Patients who are on antiperkinson drug
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neuropsychological tests -Rey-Osterrieth Complex Figure Test -Rey Auditory Verbal Learning Test -Trail Making Test -Modified Stroop Test -Word Fluency Test -Digit Span -Brown-Peterson Task -Reflection Task -Sense of agency Task Neuroeconomics Related Task: performance and the brain activation in ventral striatum and prefrontal lobe during the task. | — |
Secondary
| Measure | Time frame |
|---|---|
| PANSS (Positive and Negative Syndrome Scale) Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Blood test | — |
Countries
Japan
Contacts
Public ContactTakaki Maeda
Keio University Department of Neuropsychiatry, School of Medicine
Outcome results
None listed